The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Subgroup analysis of AURIGA: D-R vs R as maintenance in newly diagnosed myeloma post-transplant
Laahn Foster, MD, Emily Couric Clinical Cancer Center, Charlottesville, VA, presents the findings of a subgroup analysis of the Phase III AURIGA study (NCT03901963), which evaluated the efficacy of daratumumab plus lenalidomide (D-R) versus lenalidomide (R) alone as maintenance therapy in newly diagnosed patients with multiple myeloma (MM) in the post-transplant setting. Dr Foster highlights that adding daratumumab to lenalidomide maintenance improved outcomes and measurable residual disease (MRD)-negative conversion rates in all analyzed subgroups. Furthermore, no significant differences in treatment duration or safety signals were observed due to age or ethnicity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
